

Modification to the Value Creation Plan Proposed as Resolution 10 for Approval at the PuriCore Annual General Meeting

PuriCore (LSE: PURI) today announces that the Board has modified the terms of the Value Creation Plan proposed as Resolution 10 to be approved at the Company's Annual General Meeting, following further consultation with shareholders.

The first change is to limit the number of ordinary shares that can be awarded under the Value Creation Plan and any other outstanding employee share schemes to 10% of the outstanding share capital of the Company. Secondly, the base price will be set at the average share price over the 30 days following the announcement of the Company's half yearly results, which are expected in early August 2013.

Details of the proposed Value Creation Plan are available in a letter from the chairman of the Remuneration Committee on PuriCore's investor website at investor.puricore.com in the Annual General Meeting section. The 2013 Annual General meeting will be held 26 June 2013.

Enquiries:

UK

FTI Consulting

Susan Stuart
Victoria Foster Mitchell
+44 (0) 20 7831 3113

US

Sage Strategic Marketing

Jennifer Guinan
+1 610.410.8111
jennifer@sagestrat.com

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, both Sterilox Fresh and FloraFresh provide savings to supermarket retailers in labour costs and improvements in inventory loss of fresh produce and floral products. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

